Regulatory Shift: ISO 80601-2-61 Updates Raise Performance Standards for Oximeters

Regulatory Shift: ISO 80601-2-61 Updates Raise Performance Standards for Oximeters

    The third edition, Amendment 1 (Edition 3.1) of ISO 80601-2-61—Medical electrical equipment — Part 2-61: Particular requirements for the basic safety and essential performance of pulse oximeter equipment—is scheduled to enter into force in the third quarter of 2026. This update represents a significant evolution in global regulatory expectations for pulse oximeters, introducing more stringent technical benchmarks and expanding clinical validation scope beyond prior iterations.

    A core advancement lies in the tightening of dynamic accuracy tolerances. Whereas Edition 3.0 permitted ±2% SpO₂ error under stable conditions and allowed wider deviations during rapid saturation changes, Edition 3.1 imposes tighter limits across clinically relevant transition rates—from 1% to 4% SpO₂/second—and requires consistent performance across multiple physiological waveforms, including simulated low-heart-rate, high-respiratory-rate, and motion-contaminated scenarios. These refinements reflect growing clinical evidence linking transient inaccuracies to delayed hypoxemia detection in critical care settings.

    Equally consequential is the formalized requirement for low-perfusion validation. Manufacturers must now demonstrate device performance at perfusion indices (PI) as low as 0.2%, validated using standardized human subject protocols compliant with ISO/IEC 17025-accredited laboratories. This mandate addresses longstanding concerns about reliability in patients with peripheral vasoconstriction, shock, or hypothermia—populations where inaccurate readings pose the highest risk of clinical mismanagement.

    From a regulatory standpoint, compliance with ISO 80601-2-61:2026 Edition 3.1 will become a de facto prerequisite for CE marking under the EU MDR and for FDA 510(k) or De Novo submissions in the United States. Notably, the standard explicitly references alignment with IEC 62304 (software lifecycle), IEC 62366-1 (usability engineering), and ISO 14971 (risk management), reinforcing its role as a holistic framework—not merely a metrological specification. Manufacturers initiating new development cycles after Q3 2026 are strongly advised to adopt the updated test protocols early, given the extended timelines associated with clinical validation and notified body review.

    In summary, ISO 80601-2-61:2026 Edition 3.1 elevates pulse oximeter standards from static benchmarking toward real-world physiological fidelity. Its emphasis on dynamic accuracy and low-perfusion robustness signals a maturing regulatory landscape—one that prioritizes patient safety through empirically grounded, clinically contextualized performance verification. Stakeholders across R&D, quality assurance, and regulatory affairs must coordinate closely to ensure timely adoption and sustained conformity.

    创作声明：内容由AI基于参考资料创作生成，请仔细甄别。